Full Text
Morbidity Endpoints (ME) in the Amnog Process in Germany- Are me Less Important in Oncology Substances?

Abstract

Authors

K Bakker T Volmer

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×